Bacille Calmette-Guerin (BCG)-associated inflammation and fibrosis: Modulation by recombinant BCG expressing interferon-gamma (IFN-γ)

Clinical and Experimental Immunology

Volumn 119, Issue 1, 2000, Pages 92-98

  Wangoo, A ^a   Brown, I N ^a,b   Marshall, B G ^a   Cook, H T ^a,c   Young, D B ^a,b   Shaw, R J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b Great Ormond Street Hospital for Children   (United Kingdom)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Bacille Calmette Guerin; Fibrosis; Interferon gamma

Indexed keywords

BCG VACCINE; COMPLEMENTARY DNA; GAMMA INTERFERON; HYDROXYPROLINE; MESSENGER RNA; NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; NOS2 PROTEIN, MOUSE; NOS2A PROTEIN, HUMAN; PRIMER DNA; RECOMBINANT VACCINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BCG VACCINATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; EXPERIMENTAL INFECTION; FEMALE; FIBROSIS; IMMUNIZATION; INFLAMMATION; LIVER GRANULOMA; MOUSE; MYCOBACTERIOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS; ANIMAL; BAGG ALBINO MOUSE; ENZYMOLOGY; GENETICS; HUMAN; IMMUNOLOGY; LIVER; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY;

ANIMALS; BASE SEQUENCE; BCG VACCINE; DNA PRIMERS; FEMALE; FIBROSIS; HUMANS; INFLAMMATION; INTERFERON TYPE II; LIVER; MICE; MICE, INBRED BALB C; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; RNA, MESSENGER; TUBERCULOSIS; VACCINES, SYNTHETIC;

EID: 0033621552     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01100.x     Document Type: Article

References (40)

1. 1 Snider DE Jr, Montague JR. The neglected global tuberculosis problem: a report of the 1992 world congress on tuberculosis. J Infect Dis 1994; 169:1189-96.
2. 2 Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 1995; 273:220-6.
3. 3 Colditz GA, Brewer TF, Berkey CS et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271:698-702.
4. 4 Kaufmann SHE, Flesch I. Function and antigen recognition pattern of L3T4+ T cell clones from Mycobacterium tuberculosis-immune mice. Infect Immun 1986; 54:291-6.
5. 5 Ottenhoff THM, Kal AB, Van Embden JDA et al. The recombinant 65 kD heat shock protein of Mycobacterium bovis BCG/M. tuberculosis is a target molecule for CD4+ cytotoxic T lymphocytes that lyse human monocytes. J Exp Med 1988; 168:1947-52.
6. 6 Barnes PF, Mistry SD, Cooper CL et al. Compartmentalization of a CD+ T lymphocyte subpopulation in tuberculous pleuritis. J Immunol 1989; 142:1114-9.
7. 7 Flynn JL, Chan J, Triebold KJ et al. An essential role for Interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178:2249-54.
8. 8 Newport MJ, Huxley CM, Huston S et al. Mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996; 335:1941-9.
9. 9 Chan J, Xing Y, Magliozzo RS, Bloom BR. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 1992; 175:1111-22.
10. 10 Bloom BR, Fine PEM. The BCG experience: implications for future vaccines against tuberculosis. In: Tuberculosis: pathogenesis, protection and control. Washington: American Society for Microbiology, 1994:531.
11. 11 Miles MM, Shaw RJ. Effect of inadvertent intradermal administration of high dose percutaneous BCG vaccine. Br Med J 1996; 312:1205.
12. 12 Marshall B, Wangoo A, Cook HT, Shaw RJ. Increased inflammatory cytokines and new collagen formation in cutaneous tuberculosis and sarcoidosis. Thorax 1996; 51:1253-61.
13. 13 Wangoo A, Cook HT, Taylor GM, Shaw RJ. Enhanced expression of type 1 procollagen and transforming growth factor beta in tuberculin induced delayed type hypersensitivity. J Clin Pathol 1995; 48: 339-45.
14. 14 Murray PJ, Aldovini A, Young RA. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines. Proc Natl Acad Sci USA 1996; 93:934-9.
15. 15 Brown CA, Brown IN. Mycobacterium bovis, BCG, modulation of murine antibody responses: influence of dose and degree of aggregation of live or dead organisms. Br J Exp Pathol 1982; 63:133-43.
16. 16 Stegemann H, Stadler K. Determination of hydroxyproline. Clin Chim Acta 1967; 18:267.
17. 17 Wangoo A, Taylor IK, Haynes AR, Shaw RJ. Upregulation of alveolar macrophage platelet derived growth factor B (PDGF B) mRNA by interferon gamma from Mycobacterium tuberculosis antigen (PPD) stimulated lymphocytes. Clin Exp Immunol 1993; 94:43-50.
18. 18 Wangoo A, Laban C, Cook HT et al. Interleukin-10 and corticosteroid induced reduction in type I procollagen in a human ex vivo scar culture. Int J Exp Pathol 1997; 78:33-41.
19. 19 McDonald JA, Broekelmann TJ, Matheke ML et al. A monoclonal antibody to the carboxyterminal domain of procollagen type I visualizes collagen-synthesizing fibroblasts. Detection of an altered fibroblast phenotype in lungs of patients with pulmonary fibrosis. J Clin Invest 1986; 78:1237-44.
20. 20 Doenhoff MJ. Granulomatous inflammation and the transmission of infection: schistosomiasis - and TB too? Immunol Today 1998; 19: 462-7.
21. 21 Orme IM. The immunopathogenesis of tuberculosis: a new working hypothesis. Trends Microbiol 1998; 6:94-7.
22. 22 Modolell M, Corraliza IM, Link F et al. Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by TH1 and TH2 cytokines. Eur J Immunol 1995; 25:1101-4.
23. 23 Green SJ, Scheller LF, Marletta MA et al. Nitric oxide: cytokine-regulation of nitric oxide in host resistance to intracellular pathogens. Immunol Letters 1994; 43:87-94.
24. 24 Nozaki Y, Hasegawa Y, Ichiyama S et al. Mechanism of nitric oxide-dependent killing of Mycobacterium bovis BCG in human alveolar macrophages. Infect Immun 1997; 65:3644-7.
25. 25 Hogaboam CM, Cheusue SW, Steinhauser ML et al. Alteration of the cytokine phenotype in an experimental lung granuloma model by inhibiting nitric oxide. J Immunol 1997; 159:5585-93.
26. 26 Yamasaki K, Edington HD, McClosky C et al. Reversal of impaired wound repair in iNOS-deficient mice by topical adenoviral-mediated iNOS gene transfer. J Clin Invest 1998; 101:967-71.
27. 27 Mulligan MS, Hevel JM, Marletta MA, Ward PA. Tissue injury caused by deposition of immune complexes is L-arginine dependent. Proc Natl Acad Sci USA 1991; 88:6338-42.
28. 28 Fukuo K, Inoue T, Morimoto S et al. Nitric oxide mediates cytotoxicity and basic fibroblast growth factor release in cultured vascular smooth muscle cells. A possible mechanism of neovascularization in atherosclerotic plaques. J Clin Invest 1995; 95:669-76.
29. 29 Furukawa K, Harrison DG, Saleh D et al. Expression of nitric oxide synthase in the human nasal mucosa. Am J Respir Crit Care Med 1996; 153:847-50.
30. 30 Hamid Q, Springall DR, Riveros-Moreno V et al. Induction of nitric oxide synthase in asthma. Lancet 1993; 342:1510-3.
31. 31 Nicholson S, Bonecini-Almeida MG, Lapa e Silva JR et al. Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. J Exp Med 1996; 183:2293-302.
32. 32 James SL, Cheever AW, Caspar P, Wynn TA. Inducible nitric oxide synthase-deficient mice develop enhanced type 1 cytokine-associated cellular and humoral immune responses after vaccination with attenuated Schistosoma mansoni cercariae but display partially reduced resistance. Infect Immun 1998; 66:3510-8.
33. 33 Orme IM, Miller ES, Roberts AD et al. T lymphocytes mediating protection and cellular cytolysis during the course of Mycobacterium tuberculosis infection. J Immunol 1992; 148:189-96.
34. 34 Huygen K, Abramowicz D, Vandenbussche P et al. Spleen cell cytokine secretion in Mycobacterium bovis BCG-infected mice. Infect Immun 1992; 148:2887-93.
35. 35 Kobayashi K, Kai M, Gidoh M et al. The possible role of interleukin (IL)-12 and interferon-gamma-inducing factor/IL-18 in protection against experimental Mycobacterium leprae infection in mice. Clin Immunol Immunopathol 1998; 88:226-31.
36. 36 Orme IM, Roberts AD, Griffin JP, Abrams JS. Cytokine secretion by CD4 T lymphocytes acquired in response to Mycobacterium tuberculosis infection. J Immunol 1993; 151:518-25.
37. 37 Rook GA, Hernandez-Pando R. T cell helper types and endocrines in the regulation of tissue-damaging mechanisms in tuberculosis. Immuno-biology 1994; 191:478-92.
38. 38 Henandez-Pando R, Orozcoe H, Sampieri A et al. Correlation between the kinetics of Th1, Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis. Immunology 1996; 89:26-33.
39. 39 Gurujeyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: down regulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res 1995; 21:791-808.
40. 40 Czaja MJ, Weiner FR, Takahashi S et al. Gamma-interferon treatment inhibits collagen deposition in murine schistosomiasis. Hepatology 1989; 10:795-800.